Notice type: 3rd Party Publications
Problem Or Issue:
Important Safety Information communication from LIPOMED GmbH on the risk of progressive multifocal leukoencephalopathy (PML) associated with Litak (cladribine)
Important Safety Information - Litak (cladribine)